Advertisement

Topics

Companies Related to "Metformin Treatment related Retinal Degeneration" [Most Relevant Company Matches] RSS

18:06 EDT 25th June 2019 | BioPortfolio

Here are the most relevant search results for "Metformin Treatment related Retinal Degeneration" found in our extensive corporate database of over 50,000 company records.

Showing "Metformin Treatment related Retinal Degeneration" Companies 1–25 of 4,800+

Extremely Relevant

Neurotech USA, Inc

Neurotech is a biotechnology company dedicated to the development of sight-saving therapeutics for chronic retinal diseases. Retinal diseases represent significant unmet medical needs for which new medical therapies are the largest market opportunity in ophthalmology. Neurotech’s lead product (NT-501) is in clinical development for the treatment of retinal degeneration, including retinitis pigme...


Georgia Retina, P.C.

The physicians of Georgia Retina specialize in the diagnosis and treatment of diabetic retinopathy, macular pucker and macular holes, age-related macular degeneration, retinal detachment, proliferative vitreoretinopathy, ocular trauma, hereditary macular disease, retinopathy of prematurity and other forms of retinal and vitreous pathologies.

Neurotech Pharmaceuticals, Inc.

Neurotech is developing sight-saving therapeutics for the treatment of chronic retinal diseases. The Company's lead product candidate, NT-501, is currently in late-stage clinical development for advanced dry age-related macular degeneration (dry AMD) and retinitis pigmentosa (RP). The Company's portfolio of product candidates also includes treatments for wet AMD. All of Neurotech's development pro...


Optos plc

Optos plc is a leading medical retinal imaging technology company. Both eye and non-eye diseases often first exhibit in the periphery of the retina. These are very difficult to detect clinically with conventional examination equipment and techniques. Optos' devices produce ultra wide-field, high-resolution images of approximately 82% of the retina, somethi...

OcuSciences, Inc.

OcuSciences, Inc., is a clinical-stage biotechnology company developing retinal imagers to identify metabolic dysfunction occurring in the retina for the detection of early disease. Its flagship device, the OcuMet Beacon, is being developed to automatically and non-invasively assess retinal metabolic function by detecting the degree of flavoprotein fluores...

Relevant

SparingVision

SparingVision is a biotechnology company focused on the discovering and development of innovative therapies for the treatment of blinding inherited retinal diseases. SparingVision is developing a gene therapy to treat retinitis pigmentosa, the most frequent inherited retinal degeneration. This genetic condition which turns to blindness has no cure at that ...

Retina Associates of Florida

Retina Associates is a state-of-the art diagnostic and treatment center as well as a leading clinical research center for macular degeneration and other retinal diseases. Its physicians are Mark Hammer, MD, Ivan Suñer, MD and Marc Peden, MD who are consistently voted "Best Doctors in America." Retina Associates of Florida has pioneered several procedures ...

Regeneron Pharmaceuticals, Inc.

Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, diseases of the eye (wet age-re...

Ocata Therapeutics, Inc.

Ocata Therapeutics, Inc. is a clinical stage biotechnology company focused on the development and commercialization of Regenerative Ophthalmology therapeutics. Ocata’s most advanced products are in clinical trials for the treatment of Stargardt’s macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. Ocataâ...

Ocata Therapeutics, Inc.

Ocata Therapeutics, Inc. is a clinical stage biotechnology company focused on the development and commercialization of regenerative ophthalmology therapeutics. Ocata’s most advanced products are in clinical trials for the treatment of Stargardt’s macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. Ocataâ...

BioTime, Inc. 

BioTime is a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases. The Company’s current clinical programs are targeting three primary sectors, aesthetics, ophthalmology and cell and drug delivery. Its clinical programs are based on two platform technologies: pluripotent cells...

BioTime Inc.

BioTime is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. BioTime’s pipeline is based on two platform technologies which encompass cell replacement and cell/drug delivery. BioTime’s lead cell replacement product candidate is OpRegen®, a ret...

Notogen Inc.

Notogen is a biotechnology company developing regenerative therapeutics for conditions related to spinal degeneration, orthopedics and sports medicine. Notogen’s lead candidate, NTG-101, is a targeted, non-surgical, non-cellular protein-based biologic for the treatment of disc degeneration disease. The product is in pre-clinical development and is cur...

BioMolecular Therapeutics, Inc.

An early-stage biopharmaceutical company, BMT is pioneering the development of novel RNAi therapeutics to prevent and treat age-related macular degeneration based on the company's proprietary technology, asymmetric shorter-duplex siRNA (asiRNA). This novel RNAi technology significantly reduces deleterious side effects triggered by conventional siRNA, especially, the stimulation of the innate immun...

RetroSense Therapeutics

RetroSense Therapeutics is a biotechnology company developing a game-changing gene therapy to restore vision in patients suffering from blindness due to retinitis pigmentosa (RP) and advanced dry age-related macular degeneration (advanced dry-AMD). There are currently no FDA approved therapies to improve or restore vision in patients with these retinal deg...

RetroSense Therapeutics, LLC

RetroSense Therapeutics is a privately-held biotechnology company developing life-enhancing gene therapies designed to restore vision in patients suffering from blindness due to retinitis pigmentosa (RP) and advanced dry age-related macular degeneration (advanced dry-AMD). There are currently no FDA approved drugs to improve or restore vision in patients w...

Eyenuk, Inc.

Eyenuk, Inc., headquartered in Los Angeles, California, is an AI diagnostic company focused on quickly and accurately identifying patients suffering from potentially blinding eye diseases and chronic diseases at the point of care. Using computer vision and machine learning expertise, the company is developing a portfolio of products based on its proprietar...

SOOFT italia S.p.A.

SOOFT italia S.p.A. a Company of OOgroup , is an Italian pharmaceutical firm specialized in the research of new solutions , in carrying out and marketing of products for general and specific eyes health.SOOFT italia S.p.A. is mainly involved in the most common ocular pathologies, ranging from anterior segment (dry eye, ocular inflammations, periocular hygi...

Diacrin Incorporated

Diacrin is developing transplantable cells for the treatment of human diseases which are characterized by cell dysfunction or cell death and for which current therapies are either inadequate or nonexistent. Products under development for the treatment of neurological disorders include: NeuroCell(TM)-PD for Parkinson's disease and NeuroCell(TM)-HD for Huntington's dise...

Clearside Biomedical Inc.

Clearside Biomedical, based in Atlanta, is a clinical-stage ophthalmic pharmaceutical company developing and commercializing targeted therapeutics for the treatment of sight-threatening diseases. Clearside treats the pathological changes to the blood retinal barrier that lead to retinal blindness by delivering therapeutics through the suprachoroidal space ...

Opsis Therapeutics

Opsis Therapeutics is a company focused on discovering and developing new medicines to restore vision to patients suffering from retinal diseases. By combining recent innovations in induced pluripotent cell (iPSC) manufacturing, retinal cell differentiation, functional biomaterials, pre-clinical models of retinal disease, and cell therapeutic delivery tech...

Second Sight

Second Sight, located in Sylmar, California, was founded in 1998 to create a retinal prosthesis to provide sight to patients blinded from outer retinal degenerations, such as Retinitis Pigmentosa and Macular Degeneration. Through dedication and innovation, Second Sight's mission is to develop, manufacture and market implantable visual prosthetics to enable blind individuals to achieve greater inde...

RetroSense Therapeutics LLC.

RetroSense Therapeutics is a privately-held biotechnology company developing life-enhancing gene therapies designed to restore vision in patients suffering from blindness due to retinitis pigmentosa and advanced dry age-related macular degeneration. There are currently no FDA-approved drugs to improve or restore vision in patients with these retinal degene...

Altris.AI

Altris.AI (Altris, Inc) is a company which applies computer vision and deep learning trained algorithms to build innovative ophthalmology diagnosis real-time support platform for the automatic, structural and quantitative analysis and detection of glaucoma, age-related macular degeneration, diabetic retinopathy and other retinal diseases on Optical Coheren...

NightstaRx Ltd

Nightstar is a private biopharmaceutical company, spun-out from the University of Oxford in 2014, focused on the development of therapies for retinal dystrophies. The Company is focused on building the world’s leading gene therapy company for the treatment of inherited retinal diseases. The Company’s lead programme is a retinal gene therapy for c...


More From BioPortfolio on "Metformin Treatment related Retinal Degeneration"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks